Phase I trial of SNC 102 [acamprosate] for tardive dyskinesia

Trial Profile

Phase I trial of SNC 102 [acamprosate] for tardive dyskinesia

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2014

At a glance

  • Drugs Acamprosate (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Feb 2014 Status changed from planning to completed, based on information in a Synchroneuron media release.
    • 08 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top